First Look at TALAPRO-3 Results: Dr. Andrew Armstrong on Top ASCO26 Research

Dr. Andrew Armstrong of Duke University analyzes the results of the TALAPRO-3 trial comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations. Read the full abstract (LBA5007) from the 2026 ASCO Annual Meeting: https://www.asco.org/abstracts-presentations/258180 For more on ASCO26, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 6, 2026_

Video Lainnya